Two women discussing efruxifermin, or EFX, in front of a whiteboard

Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

Filter

Nov 2024 | From Akero Therapeutics

AI and Digital-Based Pathology Corroborate Reduction in Fibrosis Observed by Conventional Pathology with Efruxifermin Treatment of Patients with F2-F3 MASH in the HARMONY Study

Jun 2024 | From Akero Therapeutics

Efruxifermin treatment improved collagen biomarkers consistent with remodelling of the extracellular matrix in patients with F2-F3 fibrosis due to MASH

May 2024 | From Akero Therapeutics

FGF21 Agonists: An Emerging Therapeutic for Metabolic Dysfunction-Associated Steatohepatitis and Beyond

Mar 2024 | From Akero Therapeutics

Efruxifermin significantly improved collagen biomarkers, consistent with beneficial ECM remodeling in patients with F2-F3 fibrosis due to MASH

Mar 2024 | From Akero Therapeutics

Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study

Feb 2024 | From Akero Therapeutics

Decreases in liver cT1 accurately reflect histological improvement induced by therapies in MASH: a multi-centre pooled cohort analysis

Close up of multichannel micropipette filling four small blue centrifuge tubes

We have developed a comprehensive clinical program to evaluate EFX as a potential treatment for MASH.